0001354488-14-005207.txt : 20141021 0001354488-14-005207.hdr.sgml : 20141021 20141021171653 ACCESSION NUMBER: 0001354488-14-005207 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20141021 DATE AS OF CHANGE: 20141021 EFFECTIVENESS DATE: 20141021 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tribute Pharmaceuticals Canada Inc. CENTRAL INDEX KEY: 0001159019 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-226901 FILM NUMBER: 141166336 BUSINESS ADDRESS: STREET 1: 544 EGERTON ST CITY: LONDON STATE: A6 ZIP: N5W 3Z8 BUSINESS PHONE: 519-434-1540 MAIL ADDRESS: STREET 1: 544 EGERTON ST CITY: LONDON STATE: A6 ZIP: N5W 3Z8 FORMER COMPANY: FORMER CONFORMED NAME: STELLAR PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060412 FORMER COMPANY: FORMER CONFORMED NAME: STELLAR INTERNATIONAL INC DATE OF NAME CHANGE: 20010910 D 1 primary_doc.xml X0707 D LIVE 0001159019 Tribute Pharmaceuticals Canada Inc. 151 Steeles Avenue East Milton A6 ONTARIO, CANADA L9T 1Y1 519-434-1540 ONTARIO, CANADA STELLAR PHARMACEUTICALS INC STELLAR INTERNATIONAL INC Corporation true Janice M. Clarke 544 Egerton Street London A6 ONTARIO, CANADA N5W 3Z8 Executive Officer Steven H. Goldman 151 Steeles Avenue East Milton A6 ONTARIO, CANADA L9T 1Y1 Director John M. Gregory 151 Steeles Avenue East Milton A6 ONTARIO, CANADA L9T 1Y1 Director Robert Harris 151 Steeles Avenue East Milton A6 ONTARIO, CANADA L9T 1Y1 Executive Officer Director John J. Kime 151 Steeles Avenue East Milton A6 ONTARIO, CANADA L9T 1Y1 Director Scott Langille 151 Steeles Avenue East Milton A6 ONTARIO, CANADA L9T 1Y1 Executive Officer Director Arnold Tenney 151 Steeles Avenue East Milton A6 ONTARIO, CANADA L9T 1Y1 Director F. Martin Thrasher 151 Steeles Avenue East Milton A6 ONTARIO, CANADA L9T 1Y1 Director Pharmaceuticals $5,000,001 - $25,000,000 06b false true true true true true Each Series A warrant is exercisable for 1 common share at an exercise price of $0.50 and each Series B warrant is exercisable for 1 common share at an exercise price of $0.60, both for a period of 24 months, subject to acceleration. false 0 6579082 0 6579082 $6,579,082 may be received upon the exercise of share purchase warrants sold inside and outside the U.S. false 13 0 0 0 false Tribute Pharmaceuticals Canada Inc. /s/Janice M. Clarke Janice M. Clarke VP Finance & Administration 2014-10-21